ERBB2 and non-small cell lung carcinoma: Pivotal clinical trials of ICI did not include patients with known HER2-alterated NSCLC; therefore, our knowledge of efficacy in this target patient population can only be derived from translational research and retrospective trials (Table 4) [101,102,103,104,105,106,107,108,109,110,111,112].